AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04672746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief MI interaction via instant communication
Description: Telephone peer counselling+referral to treatment if required+The interaction communication using brief motivational interviewing via the chatting function of instant messaging apps (e.g., WhatsApp, WeChat). The intervention will last for 6 month with a frequency of at least twice a week.
Study NCT04672746 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: General health information
Description: Telephone peer counselling+referral to treatment if required+general health information via SMS, such as do physical exercise for at least 30 min per week will keep you healthy for 6 month with a frequency of least twice a week.
Study NCT05349318 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric oxygen therapy
Description: Each session will include exposure of 90 minutes to 100% at 2 ATA, with 5 minutes air breaks every 20 minutes
Study NCT05349318 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Each session will include exposure of 90 minutes to 21% at 1.2 ATA during the first five minutes of the session with the noise of circulating air, and then decrease slowly during the next five minutes to 1.03 ATA
Study NCT05262595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0471-0119 B
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study NCT05262595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0471-0119 D
Description: NNC0471-0119 administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study NCT05262595 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faster aspart
Description: Faster aspart administered once via an insulin pump as one bolus dose on top of a continuous basal rate.~The study will last 1-4 months
Study NCT04736537 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4DCT
Description: CT imaging conceptually similar to time-lapse photography.
Study NCT05461560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Sucrose solution
Description: 50 g of sucrose dissolved in 500 ml of tap water
Study NCT05461560 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed extract in sucrose solution
Description: 1 g of seaweed extract in solution of 50 g of sucrose in 500 ml of tap water
Study NCT05352529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The MapHabit system
Description: The MapHabit System (MHS) is a commercially available visual mapping software application that utilize visual, audio, and text media to create step-by-step visual guides to assist individuals and their caregivers in structuring and accomplishing activities of daily living (ADLs). The goal of the application is to develop and facilitate habits and routines using structured visual and auditory stimuli that can be customized by the user and can include educational and lesson-based material in addition to ADLs. The application was made available to families through compatible smartphones and tablets.~The MHS is a general wellness product and there is no regulatory oversight of the MapHabit System mapping functionality. This functionality is not a regulated medical device.
Study NCT05315856 — intervention group
Intervention type: BIOLOGICAL
Intervention: either BNT162b2 or ChAdOx1 vaccine
Description: Either BNT162b2 or ChAdOx1 was assigned to each participant by the Korean governmental policy, not allowing personal choice. Sixty participants were vaccinated with two doses of the ChAdOx1 (AstraZeneca) at 12-week intervals, and the remaining sixty were immunized with the BNT162b2 (Pfizer-BioNTech) vaccine at 3-week interval.
Study NCT05352529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dementia educational videos
Description: Investigators collected publicly available educational videos regarding dementia-related caregiving and support. The videos were made available to participants through compatible tablets.
Study NCT06078683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C8 Ketone Supplement
Description: Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the supplement twice a day for 6 weeks. The supplement is a C8 Ketone Diester supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein. For the proposed studies all participants will drink 5.4 oz of supplement, delivering 50g of C8 Ketone Supplement daily in a split serving fashion where half will be consumed in the morning with breakfast, and the other half with lunch.
Study NCT06078683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink the placebo twice a day, once at breakfast, and once around lunch time for 6 weeks. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any ketones (BHB), which will be replaced with a similar caloric content of fat in the form of canola oil.
Study NCT04815668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture group
Description: Sterile single-use stainless steel needles (size 0.35 mm × 55 mm) (YiDaiFu brand, Suzhou Tianyi Acupuncture Instrument Co., Ltd., Suzhou, China) will be utilized. Participants in lateral position, the acupoints area will be sterilized with 75% alcohol. To stimulate SPG, the needles will be inserted in the medial superior anterior direction to a depth of approximately 55 mm33 until the participants report a special sensation radiating toward the nose or the upper teeth. After that, the needle will be withdrew slightly. The needles will be retained for 30 minutes after three stimulation. Rescue medication are permitted when participants feel that their symptoms are intolerable.
Study NCT06078683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester Acute
Description: Nutritional and Dietary Manipulation:~Participants will undertake a controlled feeding intervention where they will drink two servings of the supplement at once (50g total C8 Ketone Supplement), and images obtained before and after consumption. The supplement is a C8 Ketone Supplement. The beverage contains 25 g of C8 Ketone Diester emulsified in a matrix of water, whey protein concentrate, modified gum acacia, natural and artificial flavors and cocoa powder. It contains 210 kcal, 0.5 g fat, 2 g carbohydrate, and 2 g protein.
Study NCT06078683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acute
Description: Participants will undertake a controlled feeding intervention where they will drink two servings of the placebo at once (50g total placebo), and images obtained before and after consumption. The placebo is flavor, energy, volume, and macronutrient matched will be given to patients as part of the placebo arm of the study. This placebo will not contain any BHB, which will be replaced with a similar caloric content of fat in the form of canola oil.
Study NCT06018831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine and Ultrasound Screening
Description: When an infant was born, he/she will receive the first urine and ultrasound screening in 3 months in Kunshan/Qidong City Maternal and Child Health Hospital.In Kunqi Cohort, 9,000 will complete 3 years follow-up(urine screening once every year, another ultrasound screening in 24-30 months). Urine sample (50ml) will be stored only once within one year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study.1,000 children will complete 6 year follow-up(receive urine and ultrasound screening once every year). Urine sample (50ml) will be stored once a year. Dry blood filter paper(120ul) will be stored once a year when he or she has a blood routine for future study. The 14 urine test items include: leukocytes, urobilinogen, microalbumin, protein, bilirubin, glucose, ascorbic acid, specific gravity, ketone bodies, nitrite, creatinine, pH, occult blood, and urinary calcium. Ultrasound test will screen for kidneys, ureters and the bladder.
Study NCT06639347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: SHR-A2102
Study NCT06639347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab injection
Description: Adebrelimab injection
Study NCT06639347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-8068 injection
Description: SHR-8068 injection
Study NCT04528082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Participants will receive apremilast orally.
Study NCT04528082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Apremilast
Description: Participants will receive apremilast orally.
Study NCT04528082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive the matching placebo orally.
Study NCT04815668 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture group
Description: The acupuncture procedure will be similar to that of the acupuncture group. After sterilizing the skin, the 0.35 × 25 mm disposable needle will be vertically inserted at SPG acupoint about 3-5 mm. No needle manipulation will be conducted to avoid the deqi response. Rescue medication are permitted when participants feel that their symptoms are intolerable.
Study NCT04815668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rescue medication group
Description: Participants in the rescue medication group do not receive acupuncture treatment during the study period. They will be only allowed to use rescue medication. They have the option of 4 weeks (up to 8 sessions) of acupuncture free of charge at the end of the follow-up period.
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 40 mg/m2/day i.v.- by vein
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 25 mg/m2/day i.v.-by vein
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 100 mg/m2 IV-by vein
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Four doses of bortezomib at a dose of 1.3 mg/m2 -injection under the skin
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Four doses of rituximab at a dose of 375 mg/m2- by vein
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 110 mg/m2 i.v-by vein
Study NCT05793151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENDURE
Description: ENDURE provides patient education through the ENDURE Patient Resource Guide and social support by linking patients to community resources (patient-level), standardizes discussions about expectations for PORT and clinical documentation to enhance communication and care coordination within and across interprofessional cancer teams (team-level), and implements referral tracking across fragmented health systems (organization-level). To facilitate care coordination, ENDURE modifies existing standard of care patient navigation (an evidence-based intervention that addresses barriers to timely cancer care) by adding PORT-focused navigation at three key care transitions: into the cancer care system; from inpatient to outpatient after surgery; and from the surgical team to the radiation oncology team.
Study NCT05156112 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure Device
Description: Each PAP treatment initiation meeting will include 1) mask fitting; 2) psycho-education to what to expect and reviewing PAP machine problem solving; and 3) setting up correct PAP treatment (e.g., auto PAP or in rare conditions, bi-level PAP).
Study NCT06450535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous onlay bone block harvesting from retromolar bone in anterior maxilla
Description: Surgical protocol ( retromolar bone harvesting) After injecting local anesthesia a crestal incision is done, from a point on the occlusal surface along the external oblique ridge and extending anteriorly and inferiorly through the buccal mucosa, parallel to the gingival margin of the mandibular molars.~The subperiosteal dissection extend to expose the ascending ramus and the retromolar region With the aid of surgical carbide burs, two proximal vertical cuts penetrating the cortex of the external oblique ridge.~The depth of penetration of the posterior cut did not exceed 2.5 mm to avoid injury to the inferior alveolar nerve.~By using microsaw , an inferior cut of 3.2 mm in depth joining the anterior and posterior vertical cuts was done.~Small perforations of 3-4 mm in depth were performed on the superior aspect of the external oblique ridge using 1 mm drill bur.~Finally, the block was sheared off using a chisel.
Study NCT06411691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRAS Vaccine with Poly-ICLC adjuvant
Description: SLP mKRASvax with Poly-ICLC adjuvant will be administered on days 1, 8, 15 and 22 in Cycle 1 (Prime Phase) and on day 1 in cycle 4 and every other cycle and beyond (Boost Phase). Up to 5 subcutaneous injections will be administered in the upper thighs, arms and/or back.~Drug: 0.3 mg per peptide vaccine + 0.5mg Poly-ICLC
Study NCT06411691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: 75 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on day 1 and day 15 during Cycle 1 in Prime Phase and on day 1 and day 15 of every cycle in the Boost Phase beginning on Cycle 2 (for a maximum of 2 years from initial vaccination).~Drug: 75 mg IV
Study NCT06411691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: 240 mg will be administered as a 30 minute IV. Infusion (-10/+25 minutes) on Cycle 1 day 1 in Prime Phase and on Cycle 2 day 1 in the Boost Phase.~Drug: 240 mg IV
Study NCT05561140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor Oral Tablet
Description: Synthetic small molecule supplied as 500 mg tablets, administered Orally
Study NCT05561140 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Cy)
Description: by vein
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (or cyclosporine)
Description: by vein
Study NCT06450535 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous cortical shell technique from retromolar bone in anterior maxilla
Description: The harvested cortical plate was then split longitudinally in two parts using a microsaw, and thinned with the bone scraper to achieve a plate of 1 mm thickness.~The plate was fixed at a distance from the residual ridge with 2 screws. Autogenous bone particles, collected with the bone scraper, were tightly packed into the gap between the plate and the recipient site.
Study NCT05659251 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Serplulimab, Albumin paclitaxel, carboplatin AUC=5, neoadjuvant therapy
Description: Serplulimab 4.5mg/kg, IV, Day 1; Albumin paclitaxel 260mg/m2, Day 1; carboplatin AUC=5, Day 1; Preoperative neoadjuvant therapy for 3 cycles, one cycle every 21 days.
Study NCT05659251 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagectomy
Description: Prior to each surgical procedure, the department engaged in comprehensive discussions and deliberations to ascertain and establish the most suitable course of action. Minimally invasive Ivor-Lewis (intrathoracic anastomosis) or McKeown (neck anastomosis) esophagectomy, including two field extensive lymphadenectomies, was performed according to the tumor location. The resection length should be at least 5cm from the tumor origin according to prechemotherapy by endoscopy.~The surgeries will be performed by surgeons with rich experience. Minimally invasive esophagectomy, can be performed using the da Vinci surgical robot, thoracoscope, or laparoscope, or by using an open approach, as judged appropriate by the surgeon.
Study NCT05659251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sample
Description: Blood, Tumour will be Collected from participant. Fate of sample is Destruction after use.~5 ml of peripheral blood was collected the day before each of the immunotherapy sessions and after surgery.~Tumour sample will be collected before neoadjuvant therapy and after surgery.
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: given by PO
Study NCT05293509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit ATG
Description: by vein
Study NCT06325709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Base-edited hematopoietic stem and progenitor cells
Description: Investigational/Study Agent: Base-edited autologous CD34 plus hematopoietic stem and progenitor cell product. The product is administered intravenously as a single infusion. This product is under an IND.
Study NCT06325709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Transplant Conditioning Agent: An alkylating chemotherapy drug to enhance engraftment of the study agent (base-edited stem cells). Conditioning will be given intravenously over 3 days with an approximate total dose of 12mg/kg. Drug levels obtained will be obtained to achieve the targeted total busulfan AUC of 65,000 ng/mL x hr.
Study NCT06325709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palifermin
Description: Mucositis Prophylaxis Agent: Intravenous infusion of keratinocyte growth factor (Palifermin) at 60 mcg/kg/day before (Days -7 to Day -5 administration of busulfan and (Days 1 to 3) post-busulfan administration to prevent oral mucositis.
Study NCT06325709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Stem Cell Mobilizing Agent: Subcutaneous administration for 6 consecutive days. It is necessary to mobilize stem cells for collection.
Study NCT06325709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Stem Cell Mobilizing Agent: Subcutaneous administration for 2 consecutive days to improve stem cell collection.
Study NCT06636266 — intervention group
Intervention type: OTHER
Intervention: Survey using a questionnaire.
Description: This research will examine any potential differences in the professional identity of Scottish chiropractors utilising the Chiropractic Professional Identity Embodiment Scale (CPIES) and the Subtype Orientation Scale (CPISOS).
Study NCT04883957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Film-coated tablets administered orally as specified in the treatment arm.
Study NCT05014412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: BCMA-CD3 bispecific antibody
Study NCT04941781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPE-307
Description: Each dose cohort will receive a single oral dose of PIPE-307. Doses to be tested in subsequent cohorts will be determined by the analysis of the exposure from PK data and the PET scans with \[11C\] PIPE-307.~Subjects will receive an intravenous dose of the radioligand \[11C\] PIPE-307 prior to PET imaging.
Study NCT04704336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-shifting strategy for HTN control (TASSH) protocol
Description: The TASSH protocol include the following 4 steps: 1). Identify HIV patients with uncontrolled HTN: trained HIV nurses will take patients' medical history (whether or not they have a diagnosis of diabetes, heart attack, stroke, heart failure, smoking). 2) Next, they will measure the patients' weight, height, waist circumference and BP with a valid automated device following standard procedures and then conduct lab tests with point-of-care testing on blood glucose, lipids and urine dip stick. 3) Initiate lifestyle counseling and medication treatment every 1-3 months: The nurses will next counsel eligible patients on lifestyle behaviors for 20 to 30 minutes (increased intake of fruits and vegetables, moderate physical activity and reduce salt intake). 4). Refer patients with complicated HTN to physicians for further care
Study NCT04734106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desert Harvest Aloe Vera Capsules
Description: 600 mg pure, freeze-dried aloe vera super-concentrate with a minimum of 200 mg glycosaminoglycan per capsule.
Study NCT04734106 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsules
Description: 550mg of Avicel microcrystalline cellulose per two-piece, hard-shelled gelatin capsule.
Study NCT06081517 — intervention group
Intervention type: BEHAVIORAL
Intervention: Social Determinants of Health and toxicity questionnaires
Description: Collect detailed clinical, and social data from patients to identify significant contributors of disparate survival and toxicity outcomes.
Study NCT06155643 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Eko Sensora
Description: The exam involves placing the stethoscope in the aortic, pulmonic, tricuspid, and mitral areas for 15-30 seconds until a green light is displayed indicating that useful sound has been recorded. The recording is then uploaded by the device using wi-fi to the AI program for analysis. It does not carry patient identifiers. The device then indicates whether a clinically significant heart murmur was heard, and if so in which recording.
Study NCT05587673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.